Graig Suvannavejh

how much of a potential springboard ATS might be, particularly from a prescribing perspective. And if you could also remind us of past comments

to be able to tap into that patient population, is there anything that you need to do, i.e., do you need to run a clinical study?

if you could remind us what the bar for success will be in that interim

could you provide a little bit more on perhaps based maybe on latest market research like where pricing, where your head is on pricing

I was curious about your gene therapy candidate for DMD and wondering how you think that might differentiate from other gene therapy approaches for DMD